PharmaCorp Rx Inc. (TSXV:PCRX)
Canada · Delayed Price · Currency is CAD 0.4700
-0.0050 (-1.05%)
Sep 3, 2026, 2:20 PM EST
PharmaCorp Rx Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 27.41 | 20.89 | 5.79 | - | - | - | |
Revenue Growth | 97.09% | 260.57% | - | - | - | - |
Cost of Revenue | 16.57 | 12.6 | 3.61 | - | - | - |
Gross Profit | 10.83 | 8.3 | 2.18 | - | - | - |
Selling, General & Admin | 10.44 | 8.19 | 3.2 | 0.58 | 0.18 | 0.08 |
Operating Expenses | 12.15 | 9.54 | 3.77 | 0.58 | 0.56 | 0.08 |
Operating Income | -1.31 | -1.24 | -1.59 | -0.58 | -0.56 | -0.08 |
Interest Expense | -0.13 | -0.06 | -0.01 | - | - | - |
Interest & Investment Income | 0.43 | 0.29 | 0.38 | 0.11 | 0.05 | 0 |
Other Non Operating Income (Expenses) | 0.25 | 0.16 | 0.06 | - | - | - |
Pretax Income | -0.77 | -0.84 | -1.16 | -0.47 | -0.52 | -0.08 |
Income Tax Expense | 0.28 | 0.59 | -0.11 | - | - | - |
Earnings From Continuing Operations | -1.05 | -1.42 | -1.05 | -0.47 | -0.52 | -0.08 |
Minority Interest in Earnings | -0.02 | -0.06 | 0.04 | - | - | - |
Net Income | -1.07 | -1.48 | -1.01 | -0.47 | -0.52 | -0.08 |
Net Income to Common | -1.07 | -1.48 | -1.01 | -0.47 | -0.52 | -0.08 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 154 | 125 | 82 | 20 | 20 | 16 |
Shares Outstanding (Diluted) | 154 | 125 | 82 | 20 | 20 | 16 |
Shares Change | 31.90% | 53.12% | 303.02% | 1.39% | 23.69% | - |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | - |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.04 | 1.92 | 0.12 | -0.52 | -0.12 | 0 |
Free Cash Flow Per Share | - | 0.01 | 0.00 | -0.03 | -0.01 | - |
Gross Margin | 39.53% | 39.72% | 37.69% | - | - | - |
Operating Margin | -4.79% | -5.92% | -27.41% | - | - | - |
Profit Margin | -3.89% | -7.09% | -17.48% | - | - | - |
Free Cash Flow Margin | 0.16% | 9.18% | 2.04% | - | - | - |
EBITDA | -0.26 | -0.41 | -1.35 | - | - | - |
EBITDA Margin | -0.95% | -1.98% | -23.23% | - | - | - |
D&A For EBITDA | 1.05 | 0.82 | 0.24 | - | - | - |
EBIT | -1.31 | -1.24 | -1.59 | -0.58 | -0.56 | -0.08 |
EBIT Margin | -4.79% | -5.92% | -27.41% | - | - | - |
Revenue as Reported | - | - | - | - | 0.05 | 0 |